{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:46:24Z","timestamp":1795113984513,"version":"4.10.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.07.051","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T08:00:24Z","timestamp":1564041624000},"page":"5288-5296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Validation of a high performance liquid chromatography method for quantitation of foot-and-mouth disease virus antigen in vaccines and vaccine manufacturing"],"prefix":"10.1016","volume":"37","author":[{"given":"Marcelo A.","family":"Spitteler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Romo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Magi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Goo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Jong","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Barroumeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel G.","family":"R\u00e9gulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Bellinzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.051_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.prevetmed.2013.07.013","article-title":"The economic impacts of foot and mouth disease - what are they, how big are they and where do they occur?","volume":"112","author":"Knight-Jones","year":"2013","journal-title":"Prev Vet Med"},{"key":"10.1016\/j.vaccine.2019.07.051_b0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1292\/jvms.11-0271","article-title":"The 2010 foot-and-mouth disease epidemic in Japan","volume":"74","author":"Muroga","year":"2011","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.vaccine.2019.07.051_b0015","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3201\/eid2012.130518","article-title":"Reemergence of foot-and-mouth disease, South Korea, 2000\u20132011","volume":"20","author":"Park","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.051_b0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7774\/cevr.2016.5.1.83","article-title":"Novel foot-and-mouth disease virus in Korea, July-August 2014","volume":"5","author":"Park","year":"2016","journal-title":"Clin Exp Vaccine Res"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.051_b0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4142\/jvs.2018.19.2.271","article-title":"Control of type O foot-and-mouth disease by vaccination in Korea, 2014\u20132015","volume":"19","author":"Park","year":"2018","journal-title":"J Vet Sci"},{"key":"10.1016\/j.vaccine.2019.07.051_b0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1099\/0022-1317-50-2-369","article-title":"Serological and immunological relationships between the 146S and 12S particles of foot-and-mouth disease virus","volume":"50","author":"Cartwright","year":"1980","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.07.051_b0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF01314726","article-title":"Comparative immunogenicity of 146S, 75S and 12S particles of foot-and-mouth disease virus","volume":"73","author":"Doel","year":"1982","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2019.07.051_b0040","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF01242904","article-title":"A study of the physical properties of the immunizing antigen of foot-and-mouth disease virus and the effect of various inactivating agents on its structure","volume":"24","author":"Wild","year":"1968","journal-title":"Arch Gesamte Virusforsch"},{"key":"10.1016\/j.vaccine.2019.07.051_b0045","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/1921163a0","article-title":"Dissociation of foot-and-mouth disease virus into its nucleic acid and protein components","volume":"192","author":"Brown","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.07.051_b0050","unstructured":"Geering WA, Lubroth J. Preparation of Foot-And-Mouth Disease Contingency Plans. FAO Animal Health Manual. Food and Agriculture Organization of the United Nations. Rome. 16th ed.; 2002. p. 8."},{"key":"10.1016\/j.vaccine.2019.07.051_b0055","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF01242879","article-title":"A simple method for the quantification of 140 S particles of foot-and-mouth disease virus (FMDV)","volume":"45","author":"Barteling","year":"1974","journal-title":"Arch Gesamte Virusforsch"},{"key":"10.1016\/j.vaccine.2019.07.051_b0060","unstructured":"European Pharmacopoeia Commission. Foot-And-Mouth Disease (Ruminants) Vaccine (Inactivated). In: European Directorate for the Quality of Medicines, editor. Eur. Pharmacopoeia. 9th ed.; 2018. p. 1062\u20133."},{"key":"10.1016\/j.vaccine.2019.07.051_b0065","unstructured":"Committee for medicinal products for veterinary use of the European Medicines Agency. Position paper on requirements for vaccines against foot and mouth disease. EMEA\/CVMP\/775\/02-FINAL. Veterinary Medicines and Inspections; 2004. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/position-paper-requirements-vaccines-against-foot-mouth-disease_en.pdf [accessed March 21, 2019]."},{"key":"10.1016\/j.vaccine.2019.07.051_b0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-1157(85)80048-2","article-title":"An international collaborative study on foot and mouth disease virus assay methods. 2. Quantification of 146S particles","volume":"13","author":"Doel","year":"1985","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2019.07.051_b0075","unstructured":"Barteling SJ. Need for further standardization of the 146-S test as the basis for final foot-and-mouth disease (FMD) vaccine formulation. Session of the Research Group of the Standing Technical Committee of EuFMD, Appendix 17 1999. http:\/\/www.biogenesisbago.com\/downloads\/BartelingSJ_146S_test_standardization_1999.pdf [accessed March 21, 2019]."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.07.051_b0080","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1038\/sj.gt.3302624","article-title":"Downstream processing of viral vectors and vaccines","volume":"12","author":"Morenweiser","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2019.07.051_b0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chroma.2016.12.085","article-title":"Quantification and characterization of virus-like particles by size-exclusion chromatography and nanoparticle tracking analysis","volume":"1487","author":"Steppert","year":"2017","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.vaccine.2019.07.051_b0090","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.chroma.2008.11.010","article-title":"Rapid high-performance liquid chromatographic analysis of adenovirus type 5 particles with a prototype anion-exchange analytical monolith column","volume":"1216","author":"Whitfield","year":"2009","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.vaccine.2019.07.051_b0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jchromb.2004.09.034","article-title":"High-performance liquid chromatographic total particles quantification of retroviral vectors pseudotyped with vesicular stomatitis virus-G glycoprotein","volume":"813","author":"Transfiguracion","year":"2004","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.vaccine.2019.07.051_b0100","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1016\/j.vaccine.2011.05.078","article-title":"Foot and mouth disease (FMD) virus: Quantification of whole virus particles during the vaccine manufacturing process by size exclusion chromatography","volume":"29","author":"Spitteler","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.051_b0105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0264-410X(90)90083-X","article-title":"Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine","volume":"8","author":"Bahnemann","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.051_b0110","unstructured":"Merck KGaA, MilliporeSigma. Benzonase\u00ae endonuclease brochure. Broch MS_BR2754EN 2018:40. https:\/\/www.emdmillipore.com\/Web-US-Site\/en_CA\/-\/USD\/ShowDocument-Pronet?id=201312.078 [accessed July 12, 2019]."},{"key":"10.1016\/j.vaccine.2019.07.051_b0115","unstructured":"FDA. Analytical Procedures and Methods Validation for Drugs and Biologics - Guidance for Industry 2015. https:\/\/www.fda.gov\/media\/87801\/download [accessed July 4, 2019]."},{"key":"10.1016\/j.vaccine.2019.07.051_b0120","unstructured":"Harris DC. Standard addition. In: H.W. Freeman & Co., editor. Quantitative Chemical Analysis; 2010. p. 106\u20138."},{"key":"10.1016\/j.vaccine.2019.07.051_b0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1440-1681.1997.tb01807.x","article-title":"Special article comparing methods of measurement","volume":"24","author":"Ludbrook","year":"1997","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.vaccine.2019.07.051_b0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/2532051","article-title":"A Concordance correlation coefficient to evaluate reproducibility","volume":"45","author":"Lin","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2019.07.051_b0135","first-page":"324","article-title":"A note on the concordance correlation coefficient","volume":"56","author":"Lin","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2019.07.051_b0140","unstructured":"McBride GB. A proposal for strength-of-agreement criteria for Lin\u2019s concordance correlation coefficient. NIWA Res Ltd; 2005. p. 1\u201310. https:\/\/www.medcalc.org\/download\/pdf\/McBride2005.pdf [accessed March 21, 2019]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:55Z","timestamp":1759401235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19309491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":28,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19309491"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a high performance liquid chromatography method for quantitation of foot-and-mouth disease virus antigen in vaccines and vaccine manufacturing","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}